Holen Sie sich die Stockscreener-App
6.375
1.19%
0.075
Vorhandelsmarkt:
6.44
0.065
+1.02%
Schlusskurs vom Vortag:
$6.30
Offen:
$6.33
24-Stunden-Volumen:
4.50M
Relative Volume:
2.41
Marktkapitalisierung:
$1.30B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-19.32
EPS:
-0.33
Netto-Cashflow:
$-51.36M
1W Leistung:
+18.94%
1M Leistung:
+54.36%
6M Leistung:
+156.02%
1J Leistung:
+85.86%
1-Tages-Spanne:
$6.18
$6.45
1-Wochen-Bereich:
$5.26
$6.605
52-Wochen-Spanne:
$1.89
$6.605
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Vergleichen Sie SVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
6.375 | 1.28B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
How strong dollar benefits Savara Inc. (YB4P) stock2025 Market WrapUp & Low Drawdown Investment Ideas - Newser
Is Savara Inc. (YB4P) stock supported by free cash flowDip Buying & Daily Price Action Insights - Newser
Savara (NASDAQ:SVRA) Shares Up 6.8%What's Next? - MarketBeat
Savara (NASDAQ:SVRA) Reaches New 1-Year HighShould You Buy? - MarketBeat
Will Savara Inc. (YB4P) stock boost dividends furtherWeekly Trade Recap & Breakout Confirmation Alerts - Newser
Is Savara Inc. stock trading near support levelsRecession Risk & AI Optimized Trade Strategies - Newser
Is Savara Inc. (YB4P) stock a top pick for value investorsEarnings Recap Summary & High Return Stock Watch Alerts - Newser
Savara (NASDAQ:SVRA) Nasdaq Today Specialized Biotech Direction - Kalkine Media
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System - BioSpace
Savara receives European patent for PAP treatment device By Investing.com - Investing.com Canada
Why analysts upgrade Savara Inc. stockTrade Volume Summary & Weekly High Return Forecasts - Newser
Savara Inc. (SVRA) Rises Amid Takeover Speculation - GuruFocus
Savara (SVRA) Market Activity Stirred by Acquisition Rumor - GuruFocus
Savara Inc. ticks higher amid takeover speculation (SVRA:NASDAQ) - Seeking Alpha
Savara rumor highlighted in Betaville blog - TipRanks
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Savara Inc. (SVRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Savara (NASDAQ:SVRA) Shares Gap DownHere's Why - MarketBeat
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Deliver - PharmiWeb.com
Savara, PARI Granted European Patent Covering Drug-Device Combination - marketscreener.com
Savara (SVRA) Secures European Patent for Drug-Device Combo - GuruFocus
Savara issues patent for Molbreevi from European Patent Office - TipRanks
Savara receives European patent for PAP treatment device - Investing.com
Is Savara Inc. (YB4P) stock a top hedge fund pickBull Run & Verified Stock Trade Ideas - Newser
Savara to Spotlight Lead Therapy in Fireside Chats at Major Healthcare Conferences - MyChesCo
Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences - Finviz
F m Investments LLC Acquires 91,830 Shares of Savara Inc. $SVRA - MarketBeat
10 Small Caps With Big Double-Digit Gains - Insider Monkey
Savara Stock Surges Amid Positive Financial Developments and Raised Price Target - timothysykes.com
Savara Inc. Sees Price Target Raised Amid Promising Drug Developments - StocksToTrade
Savara Inc’s Stock Boosted by Strategic Financial Moves and Developments - StocksToTrade
Savara (NASDAQ:SVRA) Sees Strong Trading VolumeHere's Why - MarketBeat
Savara’s Strategic Moves Strengthen Market Position with Price Target Increase - timothysykes.com
Savara Stock: Will It Continue to Rise? - StocksToTrade
Savara Inc. (SVRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Savara Inc (SVRA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Savara Inc stock hits 52-week high at 5.51 USD By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Is Investigating Savara Inc. (SVRA) And Encourages Investors to Connect - ACCESS Newswire
Savara (NASDAQ:SVRA) Hits New 12-Month HighHere's What Happened - MarketBeat
Savara Advances MOLBREEVI Toward Approval as Financing Boost Extends Cash Runway - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Savara Inc. (SVRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Securities Lawsuit Alert: Savara Inc. (SVRA)Contact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Levi & Korsinsky Invites Investors to SueWallSt After Savara Inc. Stock Collapse - The National Law Review
Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Savara Announces Participation in Upcoming December 2025 Investor Healthcare Conferences - BioSpace
Applying sector rotation models to Savara Inc.2025 Pullback Review & Accurate Intraday Trading Signals - newser.com
Global NTM Infections Pipeline Poised for Growth as Breakthrough Therapies Advance Toward Late-Stage Development, states DelveInsight - The Globe and Mail
Savara Announces Participation in Upcoming Investor Healthcare Conferences - Bluefield Daily Telegraph
Savara (NASDAQ:SVRA) Shares Up 7.3%Still a Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Savara Inc. (SVRA) And Encourages Stockholders to Connect - ACCESS Newswire
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Savara Inc-Aktie (SVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Nov 14 '25 |
Option Exercise |
1.46 |
5,860 |
8,556 |
121,326 |
| Hawkins Richard J | Director |
Jun 20 '25 |
Buy |
2.04 |
48,225 |
98,572 |
115,466 |
| McCracken Joseph S | Director |
May 29 '25 |
Buy |
2.08 |
10,000 |
20,825 |
260,837 |
| RAMSAY DAVID A | Director |
Mar 31 '25 |
Buy |
2.77 |
150,000 |
416,250 |
2,513,642 |
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):